# Bioinformatic Analysis of Contrasting Expression Patterns and Molecular Interactions of TIMPs in Breast Cancer: Implications for Tumor Progression and Survival

**Authors:** Lorena Cayetano-Salazar, Jhactcidi Jackeline García-López, Dania A. Nava-Tapia, Eymard Hernández-López, Caroline Weinstein-Oppenheimer, Julio Ortiz-Ortiz, Marco Antonio Leyva-Vázquez, Miguel Ángel Mendoza-Catalán, Adán Arizmendi-Izazaga, Napoleón Navarro-Tito

PMC · DOI: 10.3390/pathophysiology33010013 · Pathophysiology · 2026-02-02

## TL;DR

This study explores how different TIMP proteins behave in breast cancer and how they relate to tumor progression and patient survival.

## Contribution

The study reveals contrasting expression patterns and unique molecular interactions of TIMPs in breast cancer subtypes.

## Key findings

- TIMP1 is overexpressed in breast tumors and linked to multiple cancer subtypes and better survival.
- TIMP2, TIMP3, and TIMP4 are downregulated, with TIMP4 showing unique correlations with MMPs and survival.
- TIMPs are associated with various signaling pathways and immune cell infiltration in breast cancer.

## Abstract

Background/Objectives: Although tissue inhibitors of metalloproteinases (TIMPs) are key regulators in breast cancer, their differential expression, clinical relevance, and molecular roles remain unclear. This study aimed to compare the expression patterns of the four TIMPs in breast cancer and evaluate their molecular interactions and associated pathways through an integrated bioinformatic analysis. Methods: The expression of TIMPs and their correlations with MMPs were analyzed using the TCGA PanCancer, cBioPortal, and GEO datasets. Associations between TIMP expression and overall survival were assessed in the TCGA Breast Invasive Carcinoma PanCancer cohort. Pathway enrichment analysis was performed using GO, KEGG, and DAVID. The relationships between immune cell infiltration, stromal cells, and TIMP expression were assessed using the EPIC algorithm. Statistical analyses were performed using R. Results:
TIMP1 was the only inhibitor overexpressed in breast tumors and showed significant associations with the Luminal B, HER2, TNBC, and normal-like subtypes, along with a modest increase across stages. TIMP2, TIMP3, and TIMP4 were downregulated in tumors. High expression of TIMP1 and TIMP4 correlated with better overall survival. TIMP1-associated genes were enriched in NF-kappa and PI3K–Akt signaling and actin cytoskeleton components. TIMP2 was linked to Hedgehog and MAPK pathways and actin-related elements. TIMP3 correlated with Hedgehog and PI3K–Akt signaling, DNA damage response, and membrane components. TIMP4 was associated with VEGF, MAPK, PI3K–Akt, DNA damage pathways, and actin organization. TIMP2 showed strong positive correlations with MMP2 and MMP14, while TIMP4 showed negative correlations with MMP1 and MMP9. Interestingly, we found a strong positive correlation between TIMP2 and TIMP3 with ADAM12, as well as between TIMP2 and TIMP3 with ADAM10, and negative correlations with ADAM15. The differential expression of TIMPs favors greater infiltration of immune cells related to tumor progression and poor prognosis in breast cancer patients. Conclusions: TIMPs display contrasting expression profiles and distinct pathway associations in breast cancer. TIMP1 emerges as the only consistently overexpressed inhibitor, while TIMP4 appears as a promising prognostic marker with unique MMP correlations that may influence tumor behaviors.

## Linked entities

- **Genes:** TIMP1 (TIMP metallopeptidase inhibitor 1) [NCBI Gene 7076], TIMP2 (TIMP metallopeptidase inhibitor 2) [NCBI Gene 7077], TIMP3 (TIMP metallopeptidase inhibitor 3) [NCBI Gene 7078], TIMP4 (TIMP metallopeptidase inhibitor 4) [NCBI Gene 7079], MMP2 (matrix metallopeptidase 2) [NCBI Gene 4313], MMP14 (matrix metallopeptidase 14) [NCBI Gene 4323], MMP1 (matrix metallopeptidase 1) [NCBI Gene 4312], MMP9 (matrix metallopeptidase 9) [NCBI Gene 4318], ADAM12 (ADAM metallopeptidase domain 12) [NCBI Gene 8038], ADAM10 (ADAM metallopeptidase domain 10) [NCBI Gene 102], ADAM15 (ADAM metallopeptidase domain 15) [NCBI Gene 8751]
- **Diseases:** breast cancer (MONDO:0004989)

## Full-text entities

- **Genes:** MMP9 (matrix metallopeptidase 9) [NCBI Gene 4318] {aka CLG4B, GELB, MANDP2, MMP-9}, TWIST1 (twist family bHLH transcription factor 1) [NCBI Gene 7291] {aka ACS3, BPES2, BPES3, CRS, CRS1, CSO}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, PTK2 (protein tyrosine kinase 2) [NCBI Gene 5747] {aka FADK, FADK 1, FAK, FAK1, FRNK, PPP1R71}, TIMP1 (TIMP metallopeptidase inhibitor 1) [NCBI Gene 7076] {aka CLGI, EPA, EPO, HCI, TIMP, TIMP-1}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, FN1 (fibronectin 1) [NCBI Gene 2335] {aka CIG, ED-B, FINC, FN, FNZ, GFND}, ADAM17 (ADAM metallopeptidase domain 17) [NCBI Gene 6868] {aka ADAM18, CD156B, CSVP, HYPT16, NISBD, NISBD1}, BCL2L1 (BCL2 like 1) [NCBI Gene 598] {aka BCL-XL/S, BCL2L, BCLX, Bcl-X, PPP1R52}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, ZEB2 (zinc finger E-box binding homeobox 2) [NCBI Gene 9839] {aka HSPC082, SIP-1, SIP1, SMADIP1, ZFHX1B}, MMP16 (matrix metallopeptidase 16) [NCBI Gene 4325] {aka C8orf57, MMP-X2, MT-MMP2, MT-MMP3, MT3-MMP}, CDH2 (cadherin 2) [NCBI Gene 1000] {aka ACOGS, ADHD8, ARVD14, CD325, CDHN, CDw325}, MMP7 (matrix metallopeptidase 7) [NCBI Gene 4316] {aka MMP-7, MPSL1, PUMP-1}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, SNAI2 (snail family transcriptional repressor 2) [NCBI Gene 6591] {aka SLUG, SLUGH, SLUGH1, SNAIL2, WS2D}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, TIMP3 (TIMP metallopeptidase inhibitor 3) [NCBI Gene 7078] {aka HSMRK222, K222, K222TA2, SFD}, MMP12 (matrix metallopeptidase 12) [NCBI Gene 4321] {aka HME, ME, MME, MMP-12}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, ADAM10 (ADAM metallopeptidase domain 10) [NCBI Gene 102] {aka AD10, AD18, CD156c, CDw156, HsT18717, MADM}, SNAI1 (snail family transcriptional repressor 1) [NCBI Gene 6615] {aka SLUGH2, SNA, SNAH, SNAIL, SNAIL1, dJ710H13.1}, IFI27 (interferon alpha inducible protein 27) [NCBI Gene 3429] {aka FAM14D, ISG12, ISG12A, P27}, ADAM12 (ADAM metallopeptidase domain 12) [NCBI Gene 8038] {aka ADAM12-OT1, CAR10, MCMP, MCMPMltna, MLTN, MLTNA}, ESR1 (estrogen receptor 1) [NCBI Gene 2099] {aka ER, ESR, ESRA, ESTRR, Era, NR3A1}, CLEC3B (C-type lectin domain family 3 member B) [NCBI Gene 7123] {aka MCDR4, TN, TNA}, TNFRSF1A (TNF receptor superfamily member 1A) [NCBI Gene 7132] {aka CD120a, FPF, TBP1, TNF-R, TNF-R-I, TNF-R55}, MAPK3 (mitogen-activated protein kinase 3) [NCBI Gene 5595] {aka ERK-1, ERK1, ERT2, HS44KDAP, HUMKER1A, P44ERK1}, MMP11 (matrix metallopeptidase 11) [NCBI Gene 4320] {aka SL-3, ST3, STMY3}, PRs [NCBI Gene 5640], AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, EREG (epiregulin) [NCBI Gene 2069] {aka EPR, ER, Ep}, MMP8 (matrix metallopeptidase 8) [NCBI Gene 4317] {aka CLG1, HNC, MMP-8, PMNL-CL}, MMP14 (matrix metallopeptidase 14) [NCBI Gene 4323] {aka MMP-14, MMP-X1, MT-MMP, MT-MMP 1, MT1-MMP, MT1MMP}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, ZEB1 (zinc finger E-box binding homeobox 1) [NCBI Gene 6935] {aka AREB6, BZP, DELTAEF1, FECD6, NIL2A, PPCD3}, MMP3 (matrix metallopeptidase 3) [NCBI Gene 4314] {aka CHDS6, MMP-3, SL-1, STMY, STMY1, STR1}, ADAM15 (ADAM metallopeptidase domain 15) [NCBI Gene 8751] {aka MDC15}, TIMP4 (TIMP metallopeptidase inhibitor 4) [NCBI Gene 7079] {aka TIMP-4}, NR4A1 (nuclear receptor subfamily 4 group A member 1) [NCBI Gene 3164] {aka GFRP1, HMR, N10, NAK-1, NGFIB, NP10}, VIM (vimentin) [NCBI Gene 7431], MMP13 (matrix metallopeptidase 13) [NCBI Gene 4322] {aka CLG3, MANDP1, MDST, MMP-13}, PGR (progesterone receptor) [NCBI Gene 5241] {aka NR3C3, PR}, HBP1 (HMG-box transcription factor 1) [NCBI Gene 26959], TIMP2 (TIMP metallopeptidase inhibitor 2) [NCBI Gene 7077] {aka CSC-21K, DDC8}, MMP1 (matrix metallopeptidase 1) [NCBI Gene 4312] {aka CLG}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, MMP2 (matrix metallopeptidase 2) [NCBI Gene 4313] {aka CLG4, CLG4A, MMP-2, MMP-II, MONA, TBE-1}, PTEN (phosphatase and tensin homolog) [NCBI Gene 5728] {aka 10q23del, BZS, CWS1, DEC, GLM2, MHAM}, ADAM8 (ADAM metallopeptidase domain 8) [NCBI Gene 101] {aka CD156, CD156a, MS2}, ADAM9 (ADAM metallopeptidase domain 9) [NCBI Gene 8754] {aka CORD9, MCMP, MDC9, Mltng}, TENM1 (teneurin transmembrane protein 1) [NCBI Gene 10178] {aka ODZ1, ODZ3, TEN-M1, TEN1, TNM, TNM1}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}
- **Diseases:** TN (MESH:C562719), bone metastasis (MESH:D009362), colorectal cancer (MESH:D015179), tumorigenic (MESH:D002471), lymph node metastasis (MESH:D008207), Breast Cancer (MESH:D001943), breast, ovarian, cervical, prostate, brain, colon, endometrial, and renal papillary tumors (MESH:D011472), pancreatic and renal clear cell tumors (MESH:D002292), node (MESH:D012804), injury to (MESH:D014947), inflammation (MESH:D007249), cervical cancer (MESH:D002583), IV tumors (MESH:D009369), carcinoma in situ (MESH:D002278), fibrosarcoma (MESH:D005354), head and neck carcinoma (MESH:D006258), mammary tumors (MESH:D015674), carcinogenesis (MESH:D063646), colon carcinoma (MESH:D003110), head and neck squamous cell carcinoma (MESH:D000077195), non-small-cell lung cancer (MESH:D002289)
- **Chemicals:** cisplatin (MESH:D002945), tissue inhibitors of (-), doxorubicin (MESH:D004317), tamoxifen (MESH:D013629)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** MCF10A — Homo sapiens (Human), Spontaneously immortalized cell line (CVCL_0598), MDA-MB-231 — Homo sapiens (Human), Breast adenocarcinoma, Cancer cell line (CVCL_0062), HT1080 — Homo sapiens (Human), Fibrosarcoma, Cancer cell line (CVCL_0317), T47D — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0553), HeLa cervical cancer — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_JX14), DLD-1 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0248), MDA-MB-435 — Homo sapiens (Human), Amelanotic melanoma, Cancer cell line (CVCL_0417), HEK293T — Homo sapiens (Human), Transformed cell line (CVCL_0063), MCF-7 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0031)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12921991/full.md

## Figures

11 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12921991/full.md

## References

83 references — full list in the complete paper: https://tomesphere.com/paper/PMC12921991/full.md

---
Source: https://tomesphere.com/paper/PMC12921991